Clinical Trial: Study Evaluating AMG 706 in Subjects with Advanced Solid Tumors


	Home	\|	Search	\|	Browse	\|	Resources	\|	Help	\|	What's New	\|	About

Study Evaluating AMG 706 in Subjects with Advanced Solid Tumors

This study is currently recruiting patients.

Sponsored by:	Amgen
Information provided by:	Amgen

Purpose

This study will determine the safety and pharmacokinetics of AMG 706 in subjects with advanced solid tumors.

Condition	Treatment or Intervention	Phase
Tumors	Drug: AMG 706	Phase I

MedlinePlus related topics: Cancer; Cancer Alternative Therapy

Study Type: Interventional
Study Design: Treatment, Open Label, Dose Comparison, Pharmacokinetics Study

Official Title: A Phase 1, First in Human, Open-Label, Dose Finding Study Evaluating the Safety and Pharmacokinetics of AMG 706 in Subjects with Advanced Solid Tumors

Eligibility

Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both

Criteria

Inclusion Criteria:

Exclusion Criteria:

Location and Contact Information

Amgen Call Center 866-572-6436

California
Research Site, Los Angeles, California, United States; Recruiting

Texas
Research Site, Houston, Texas, United States; Recruiting

More Information

AmgenTrials clinical trials website

Center Watch Clinical Trials Listing Service

Study ID Numbers: 20030116
Record last reviewed: October 2004
Record first received: October 6, 2004
ClinicalTrials.gov Identifier: NCT00093873
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-11-10

U.S. National Library of Medicine, Contact NLM Customer Service

National Institutes of Health, Department of Health & Human Services